Our study establishes tumor cell-expressed TRAIL-R as a trigger for cancer cells to secrete CCL2, which, in turn, drives accumulation of a pro-tumorigenic immune microenvironment via host cell-expressed CCR2. This evidence concerns the gene CCR2 and neoplasm.